MOTS-c Dosage: What the Research Actually Administered

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded not in nuclear DNA but inside the mitochondrial genome itself. It belongs to a small family of mitochondrial-derived peptides that also includes humanin and the SHLP series. Its sequence, MRWQEMGYIFYPRKLR, corresponds to a short open reading frame within the 12S ribosomal RNA gene, and its molecular weight of roughly 2174.6 g/mol places it firmly in the small-peptide range. A full biochemical profile is available in our MOTS-c guide.

The peptide entered the literature in 2015, when Changhan Lee and colleagues described it in Cell Metabolism as a regulator of insulin sensitivity and metabolic homeostasis acting through the folate-methionine cycle, AICAR accumulation and AMPK activation. A later paper from the same group showed that under metabolic stress MOTS-c translocates to the nucleus and modulates nuclear gene expression, which positioned it as a signaling molecule rather than a simple metabolic byproduct.

So why does the dosage question remain open eleven years later? Three reasons stack on top of each other. First, essentially all dose-response data come from rodents, and the dominant administration route in those studies is intraperitoneal injection, which has no practical human counterpart. Second, no pharmacokinetic study of exogenous MOTS-c in humans has been published: half-life, bioavailability, clearance and volume of distribution are simply unknown. Third, the single clinical program that reached human testing used a modified analog rather than native MOTS-c, and its dosing details were never published in a peer-reviewed venue.

This matters because search demand for the topic is real and multilingual. Readers looking up MOTS-c Dosierung in Germany, dosaggio MOTS-c in Italy, dawkowanie MOTS-c in Poland or MOTS-c como usar in Spanish and Portuguese markets all arrive at the same underlying question, and they frequently land on pages that present forum numbers as though they were clinical guidance. The purpose of this article is the opposite: to separate what was actually administered in documented research from what circulates as unverified practice.

Educational note: this content is for informational purposes only. MOTS-c is not approved for human use by the FDA or the EMA, and nothing here constitutes a dosing recommendation.

The reference point for almost every MOTS-c dosage discussion is the 2015 Cell Metabolism paper by Lee and colleagues. In the diet-induced obesity arm of that work, mice fed a high-fat diet received 0.5 mg/kg per day by intraperitoneal (IP) injection. Treated animals showed reduced diet-induced obesity, improved insulin sensitivity and changes in skeletal muscle glucose handling relative to vehicle controls. Other experiments within the same paper used acute administration and higher milligram-per-kilogram exposures depending on the endpoint being measured, which is standard practice in mechanistic rodent work.

The second pillar is the 2021 Nature Communications study by Reynolds and colleagues, which examined MOTS-c as a regulator of age-dependent physical decline. That group treated young, middle-aged and older mice with intraperitoneal MOTS-c over multi-week periods, in the single-digit milligram-per-kilogram-per-day range, and reported improvements in physical capacity and measures of muscle homeostasis in the older animals. Again, the route was intraperitoneal and the schedule was daily or near-daily.

A point that is routinely mishandled online: a milligram-per-kilogram figure from a mouse does not transfer one-to-one to a human. Interspecies scaling uses body surface area rather than body weight, and regulatory guidance applies a conversion factor of roughly 12.3 when moving from mouse to human. Even after that correction, the result is a starting point for designing a first-in-human trial, not a dose for a person. The intraperitoneal route compounds the problem, because absorption kinetics from the peritoneal cavity differ substantially from subcutaneous delivery.

In short: the animal literature tells you what researchers gave to mice under controlled conditions with defined endpoints. It does not tell you what is appropriate, safe or effective in a human being, and it was never designed to.

The short answer is no. There is no validated human dose for MOTS-c, no published human pharmacokinetic profile, and no regulatory approval in any major jurisdiction. Anyone presenting a specific milligram figure as a human protocol is extrapolating, not citing.

The closest the field has come is CB4211, a modified analog of MOTS-c developed by CohBar. CB4211 entered a Phase 1a/1b clinical trial registered as NCT03998514, evaluating safety, tolerability and preliminary metabolic effects in participants with obesity and nonalcoholic fatty liver disease. The company announced topline results in 2021 describing statistically significant effects on body weight and liver fat relative to placebo in the Phase 1b portion. Two caveats are decisive here. First, CB4211 is an engineered analog with altered properties, not native MOTS-c, so its dosing does not transfer. Second, the results were communicated as a topline corporate announcement rather than a full peer-reviewed publication, and no validated oral or subcutaneous dose for human use emerged from it.

What does exist in humans is observational data on endogenous MOTS-c. Ramanjaneya and colleagues reported in 2019 that circulating mitochondrial-derived peptide levels, including MOTS-c, are lower in people with type 2 diabetes than in controls. Reynolds and colleagues measured increases in plasma and skeletal muscle MOTS-c in healthy men following acute exercise. These are measurements of what the body produces on its own. They describe concentrations in nanograms per milliliter, not administered doses, and they cannot be converted into an injection protocol.

Oral MOTS-c deserves a specific note, because oral capsules are marketed. There is no published human bioavailability study for orally administered MOTS-c. As a 16-amino-acid peptide without protective modification, it is a plausible substrate for gastric and intestinal proteases, and the burden of proof sits with anyone claiming meaningful systemic absorption. Absence of evidence here is genuinely absence of evidence.

Genetic context adds another layer. Zempo and colleagues described a mtDNA polymorphism (the m.1382A>C variant common in some East Asian populations) that alters the MOTS-c sequence and associates with metabolic phenotype, which suggests that responses to MOTS-c signaling may vary by genotype. That is one more reason a single universal dose figure would be biologically implausible even if trials existed.

A large share of the confusion in peptide forums is not pharmacology at all. It is unit arithmetic. Research vials are labeled in milligrams, most published preclinical work is expressed in milligrams per kilogram, and community discussions frequently switch to micrograms without flagging the change. The conversion itself is trivial and fixed: 1 mg = 1000 mcg, for every peptide, always.

The table below is pure arithmetic. It converts mass units and nothing more. It is not a dosing table, it does not indicate what quantity anyone should use, and it says nothing about concentration, which depends entirely on how much solvent is added.

Two further unit traps are worth naming. The first is the insulin syringe. A standard U-100 insulin syringe is graduated in insulin units, where 100 units correspond to 1 mL of volume. Those units measure liquid volume, not peptide mass, so a given number of units on the barrel means a completely different quantity of peptide depending on how concentrated the vial is. The second is the symbol µg, which is identical to mcg. Seeing both notations in the same thread makes some readers assume they are different quantities.

For a broader reference on how dosing units are expressed across different research peptides, see our peptide dosage chart. For MOTS-c specifically, the arithmetic linking vial mass, solvent volume and concentration is handled in the MOTS-c reconstitution calculator, which performs the computation without implying that any particular result is appropriate to use.

MOTS-c is supplied as a lyophilized powder, a freeze-dried cake or film at the bottom of a sealed glass vial. In that state it is relatively stable. Once liquid is introduced, it becomes a solution with a finite shelf life and a concentration that depends entirely on arithmetic the buyer performs themselves. Vials in circulation are commonly labeled 5 mg, 10 mg or 40 mg, and the same peptide mass can produce very different concentrations depending on the volume added.

The underlying relationship is one line of algebra: concentration equals peptide mass divided by solvent volume. Add half as much liquid and the solution is twice as concentrated. This is why two people can both say they used the same vial and mean entirely different things. Because the appropriate concentration depends on the quantity someone intends to measure, and because this article does not recommend any quantity, we do not publish specific volume figures here. The MOTS-c calculator performs the computation for whatever vial size and target you enter, and shows the resulting concentration explicitly.

The mechanics of the process are standard across research peptides and are covered step by step in our peptide reconstitution guide. The essentials: let a refrigerated vial reach room temperature before opening, disinfect the rubber stopper, introduce the solvent slowly down the inner glass wall rather than spraying it directly onto the powder, and allow the cake to dissolve on its own. Gentle swirling is acceptable if dissolution is slow. Vigorous shaking is not, because mechanical shear and foaming can denature peptides in solution.

Solvent choice matters for storage duration. Bacteriostatic water contains 0.9 percent benzyl alcohol as a preservative and is intended for multi-dose vials. Plain sterile water contains no preservative and is appropriate only for single use. Whichever is used, reconstituted peptide belongs in the refrigerator, protected from light, with the reconstitution date written on the vial. Do not rely on memory for that date.

The 40 mg vial deserves a specific warning. High-mass vials concentrate risk: any arithmetic error is multiplied by the larger quantity in the vial, and a solution that sits in the refrigerator for many weeks accumulates more degradation exposure than a smaller vial finished quickly. Larger is not simply better value.

In the published animal work, the pattern is consistent and simple: daily or near-daily intraperitoneal injection, sustained over periods ranging from days to several weeks depending on the endpoint. Lee and colleagues used daily dosing in the high-fat-diet model. Reynolds and colleagues used repeated injections across multi-week treatment windows in aged mice. There is no published study establishing an optimal interval, an optimal time of day, or a rationale for cycling on and off.

Community protocols circulating on forums and social platforms look different. The most frequently repeated pattern is roughly 5 to 10 mg per week, divided across several administrations, typically by subcutaneous injection, sometimes with a five-days-on and two-days-off schedule, and often timed before training sessions on the theory that MOTS-c amplifies exercise signaling.

Explicit flag: these community figures are not clinically validated. They do not originate from any trial. They have no published safety data behind them, no pharmacokinetic justification for the interval chosen, and no dose-response evidence in humans supporting the total weekly quantity. They are documented here because readers encounter them and deserve to know their actual provenance, not because they represent a defensible protocol. Treating a number as credible because it is widely repeated is exactly the failure mode this section exists to prevent.

The timing question is particularly untethered. Pre-workout administration is a reasonable-sounding hypothesis derived from the exercise-mimetic literature, but no human study has compared pre-exercise to post-exercise to rest-day administration for any outcome. Without a known human half-life, there is no pharmacological basis for choosing one window over another. Any claim that a specific time of day is superior is speculation presented with false precision.

The honest position is that frequency and timing for human use are undefined. The animal schedules were chosen to suit experimental designs in mice, not to optimize anything for a person, and translating them directly ignores every difference in route, metabolism and body size between the two species.

MOTS-c is frequently described as an exercise mimetic, and that framing traces almost entirely to the 2021 Nature Communications paper by Reynolds and colleagues. That study made two distinct observations that are often merged incorrectly in popular summaries, so it is worth separating them.

The first observation is correlative and human. In healthy men, plasma MOTS-c concentrations and skeletal muscle MOTS-c levels increased following acute exercise. This positions MOTS-c as an exercise-responsive endogenous signal: the body produces more of it when muscle is worked. That finding says nothing about what happens when the peptide is injected.

The second observation is interventional and murine. Older mice given MOTS-c intraperitoneally over a multi-week period showed improvements in physical performance measures and in markers of muscle homeostasis compared with untreated age-matched animals. Combined with earlier data on AMPK activation and glucose handling, this is the mechanistic basis for the exercise-mimetic label. It is a mouse result, produced by a route unavailable to humans, at exposures never tested in people.

The distinction matters for how the peptide is marketed. "MOTS-c rises with exercise in humans" and "MOTS-c improves running capacity in old mice" are both true. "Injecting MOTS-c improves human exercise capacity" has not been demonstrated. That third statement is the one that sells product, and it is the one with no supporting human trial. Readers evaluating claims in the broader metabolic peptide space may find our overview of peptides discussed for fat loss useful for the same reason: the gap between mechanism and demonstrated human outcome is where most overstatement lives.

There is also a plausible biological ceiling worth considering. If MOTS-c is part of a feedback system the body already engages during exercise, supplementing it exogenously may not produce additive effects, and the shape of any dose-response curve, including whether higher exposures reduce benefit, is entirely unmapped. Nobody has measured it in humans.

Most problems people report with research peptides are handling problems rather than pharmacological ones. The errors below appear repeatedly and are all avoidable.

• Shaking the vial. Mechanical agitation and foaming can denature peptide in solution. Introduce solvent slowly against the glass wall and let the cake dissolve; swirl gently only if needed.
• Spraying solvent directly onto the powder. A forceful stream onto the lyophilized cake causes localized shear. Aim for the wall of the vial.
• Confusing bacteriostatic and sterile water. Only bacteriostatic water contains a preservative. Reconstituting a multi-use vial with plain sterile water creates a contamination risk that grows with every subsequent puncture.
• Confusing insulin units with peptide mass. A U-100 syringe measures volume, where 100 units equals 1 mL. The same number of units corresponds to a completely different peptide quantity at a different concentration. This is the single most common arithmetic failure.
• Recomputing concentration incorrectly after a top-up. Adding more solvent to a partially used vial invalidates the original figure. The calculation has to be redone from the remaining mass.
• Not equilibrating a cold vial. Opening a vial straight from the refrigerator draws condensation into it. Let it reach room temperature first.
• Failing to date the vial. Reconstituted peptide has a finite refrigerated shelf life. Without a written date, that window becomes guesswork.
• Light and heat exposure. Leaving a reconstituted vial on a counter, in a car or near a window accelerates degradation.
• Reusing needles. Beyond infection risk, a blunted needle increases tissue trauma and injection-site reactions.
• Skipping third-party verification. Research-grade material varies in purity and in actual peptide content. A recent certificate of analysis with HPLC purity and mass spectrometry identity confirmation is the minimum, and even that does not make a substance approved for human use.

A cloudy solution, visible particulates, a cake that will not dissolve, or a vial with a compromised seal are all reasons to discard rather than troubleshoot. Our five-step reconstitution walkthrough covers the correct sequence in detail, and the MOTS-c calculator removes the arithmetic step where most of these errors originate.

Because MOTS-c has no approved indication and no human safety database, there is no established adverse event profile, no known contraindication list and no documented drug interaction data. That is not the same as a favorable safety record. It means the relevant studies have not been done, and an absence of reported problems in an unmonitored population is not evidence of safety.

Several situations warrant a conversation with a qualified healthcare professional before considering anything in this category. Anyone taking glucose-lowering medication, including insulin or sulfonylureas, should note that MOTS-c acts on insulin sensitivity in preclinical models, which raises a theoretical concern about additive hypoglycemic effects that has never been formally studied. People with a history of malignancy should be aware that AMPK and metabolic signaling pathways intersect with cell proliferation biology in ways that are not fully characterized for this peptide. Pregnancy and breastfeeding have no safety data whatsoever. Significant renal or hepatic impairment alters peptide clearance in ways that cannot be predicted here.

Seek prompt medical attention for signs of an injection-site infection, including spreading redness, warmth, swelling, discharge or fever. Symptoms suggesting hypoglycemia, such as tremor, sweating, confusion or palpitations, also warrant immediate evaluation. Any allergic-type reaction, including hives, facial swelling or difficulty breathing, is an emergency.

Legal status is a separate matter from safety. MOTS-c is classified for research use only in the United States and across the European Union, and it has not been approved by the FDA or the EMA for any human indication. Import rules, possession rules and supply rules differ substantially between countries, and are your responsibility to verify. Competitive athletes should note that the WADA Prohibited List includes an S0 category covering any pharmacological substance not currently approved by a governmental regulatory health authority for human therapeutic use, which captures substances in this class regardless of whether they are named individually.

Medical disclaimer: this article is for educational purposes only and does not constitute medical advice. It documents what published research administered and what circulates in unverified community practice, and it deliberately recommends no dose. MOTS-c is a research peptide that is not approved for human use. Consult a qualified healthcare professional before making any decision related to your health.